関連する実験動画

Updated: Feb 25, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

AMLにおけるブスルファン耐性は,ミトコンドリアのコピー数と脂質代謝の変化と関連しています

Vid Mlakar1, Simona Jurković Mlakar2,3, Yvonne Gloor2

  • 1CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Geneva, Switzerland. vid.mlakar@unige.ch.

Scientific reports
|February 23, 2026
PubMed
まとめ

急性骨髄性白血病 (AML) 細胞におけるブスルファン耐性は,ミトコンドリアDNA複製数 (mtDNA-CN) の増加と関連しています. この研究では,ブスルファン (BU) 耐性にはmtDNA-CNと遺伝子発現の変化が伴うことが明らかになり,潜在的な治療標的を提供している.

キーワード:
MTND1 MTND1 MTND1 と呼ばれるものです.獲得した化学抵抗性.急性骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,骨髄性白血病 (Acute Myeloid Leukemia) とは,ブスルファンはブスルファン.コレステロール コレステロールサイトラビンは,サイトラビンのIC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50MOLM-13は,モルム13と呼ばれるものです.ミトコンドリアはミトコンドリアです.

さらに関連する動画

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

849

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.2K